CoImmune, MSK will collaborate on CAR-CIK therapies to treat solid tumors

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

CoImmune, Inc. and Memorial Sloan Kettering Cancer Center entered a license and collaboration agreement to accelerate the adaptation of CoImmune’s proprietary allogeneic CAR-CIK technology platform to treat solid tumors.  

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login